2nd Quarter - Report

W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Financial Institutions/Investments/Securities FIN

FY 2017 Financial Services Appropriations bill.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Promoted life sciences community and communicated economic and health benefits of the industry. S.1878: Advancing Hope Act of 2016 - "To extend the pediatric priority review voucher program". H.R. 6: 21st Century Cures Act and Senate HELP Committee Innovation effort to promote medical innovation for patients, specifically with respect to reforms at NIH. Education about need for incentives for antibiotic development. Education on Bayh-Dole Act as it relates to "march in rights" at NIH. S.524: Comprehensive Addiction and Recovery Act of 2016, as it relates to Rx take back programs. Education about the value of innovative new medicines. Education about FDA performance on review of drugs and medical devices. H.R.3299: Strengthening Public Health Emergency Response Act of 2015.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1878 (114th), H.R. 3299 (114th), S. 524 (114th), H.R. 6 (114th)

Medicare/Medicaid MMM

March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5122 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.